Batoclimab is a Monoclonal Antibody owned by HanAll Biopharma, and is involved in 22 clinical trials, of which 6 were completed, 7 are ongoing, and 9 are planned.
Batoclimab is an anti-FcRn fully human monoclonal antibody. FcRn is involved in the transfer of passive humoral immunity. It exerts a triple mode of action by blocking FcRn through the increase the catabolism of pathogenic autoantibodies in circulation, suppressing the immune complex-mediated humoral and cellular immunity and by decreasing the glomerular immune complex deposition and inflammatory responses.
The revenue for Batoclimab is expected to reach a total of $3.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Batoclimab NPV Report.
Batoclimab is originated and owned by HanAll Biopharma. Immunovant is the other company associated in development or marketing of Batoclimab.
Batoclimab is under development for the treatment of idiopathic thrombocytopenic purpura (ITP), membranous nephropathy, warm autoimmune hemolytic anemia, pemphigus vulgaris, lupus nephritis (LN), myasthenia gravis (MG), Graves' ophthalmopathy, chronic inflammatory demyelinating polyneuropathy (CIDP) and neuromyelitis optica (NMO). It is a fully human monoclonal antibody IgG1 targeting the Fc neonatal receptor (FcRn). It is administered subcutaneously and developed based on OmniAb technology.
Immunovant is a biopharmaceutical company that focus on developing antibodies for the treatment of autoimmune diseases. The company’s pipeline products include IMVT-1401, a fully human monoclonal antibody that targets the neonatal Fc receptor (FcRn), in Phase II clinical trials for the treatment of myasthenia gravis and thyroid eye disease. It is also evaluating its IMVT-1401 in IND Phase for the treatment of warm autoimmune hemolytic anemia. The company seeks to collaborate with HanAll Biopharma Co Ltd for research and development of next generation FcRn inhibitors. The company has subsidiaries located in Switzerland, Bermuda and the US. Immunovant is headquartered in New York City, New York, the US.
The operating loss of the company was US$156 million in FY2022, compared to an operating loss of US$108.1 million in FY2021. The net loss of the company was US$156.7 million in FY2022, compared to a net loss of US$107.4 million in FY2021.
Quick View – Batoclimab
|Highest Development Stage|